OncoMatch/Clinical Trials/NCT06518551
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Is NCT06518551 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Elotuzumab and Iberdomide for myeloma.
Treatment: Elotuzumab · Iberdomide · Dexamethasone — The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulating agent
at least 4 prior lines of anti-myeloma treatment including immunomodulating agent
Must have received: proteasome inhibitor
at least 4 prior lines of anti-myeloma treatment including ... a proteasome inhibitor
Must have received: anti-CD38 monoclonal antibody
at least 4 prior lines of anti-myeloma treatment including ... an anti-CD38 monoclonal antibody
Must have received: CAR-T cell therapy (ide-cel)
patient has received ide-cel in accordance with the FDA approved US Prescribing Information and has achieved at least a partial response, and is within 90 days of infusion
Cannot have received: Iberdomide (Iberdomide)
Prior exposure to Iberdomide
Cannot have received: peripheral stem cell transplant
Exception: within 12 weeks
Prior peripheral stem cell transplant within 12 weeks
Cannot have received: allogeneic stem cell transplantation
Exception: with active graft-versus-host-disease
Prior allogeneic stem cell transplantation with active graft-versus-host-disease
Lab requirements
Blood counts
ANC 1,000 cells/dL (no growth factors within 7 days); Platelet count 75,000 cells/dL (no transfusions within 7 days); Hemoglobin 8.0 g/dL (RBC transfusions permitted)
Kidney function
Creatinine clearance 30 ml/min (Cockroft-Gault formula)
Liver function
Total Bilirubin 1.5 X ULN (except Gilbert Syndrome <3.0 mg/dL); AST or ALT 3x ULN
Screening Laboratory evaluations within the following parameters: ANC 1,000 cells/dL (no growth factors within 7 days); Platelet count 75,000 cells/dL (no transfusions within 7 days); Hemoglobin 8.0 g/dL (RBC transfusions permitted); Total Bilirubin 1.5 X ULN (except Gilbert Syndrome <3.0 mg/dL); AST or ALT 3x ULN; Creatinine clearance 30 ml/min (Cockroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify